IP Library Granted Patent US 9,681,647
Granted Patent B2
US 9,681,647 · App. 14/412,312 · Granted Jun 20, 2017

Mammal with an orthotopic tumor capable of metastasis, a method of making and a method of using

Inventors: Huanhuan Chen (Flushing, NY); Steven M. Lipkin (Scarsdale, NY); Xiling Shen (Ithaca, NY)
Assignee: Cornell University
A01K67/0278A01K67/0271A61K49/0008C07K14/7158C12N15/1138A01K2207/12A01K2227/105A01K2267/0331C12N2310/14C12N2310/531C12N2740/15043C12N2830/003
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,681,647
App. No.
14/412,312
Granted
Jun 20, 2017
Kind
B2
Abstract

Provided are compositions and methods that involve cancer cells which are modified so that they can form orthotopic tumors in a non-human mammal, and wherein metastasis of the tumor can be controlled. The cancer cells, which may be human cancer cells, are modified so that expression of a human chemokine receptor can be modulated. Modulating expression of the human chemokine receptor allows selective initiation of metastasis. Kits which contain the modified cancer cells are provided. A method for identifying agents which can inhibit metastasis using non-human mammals having orthotopic tumors formed using the modified cancer cells is also included.

Claims (4)

1. A method for making a non-human mammal comprising an orthotopic tumor in its gastrointestinal tract that metastasizes to the lungs and/or liver comprising:

a) introducing into a non-human mammal a plurality of human Chemokine Receptor 9 positive (CCR9+) colorectal cancer cells, wherein subsequent to the introduction the human colorectal cancer cells form a tumor in the gastrointestinal tract of the non-human mammal, wherein the cancer cells contain an expression vector, wherein the expression vector comprises an inducible promoter that controls expression of an shRNA targeted to the human CCR9, the method further comprising inducing the expression of the shRNA such that the tumor metastasizes to the lungs and/or liver.

2. A non-human mammal comprising an orthotopic a tumor in its gastrointestinal tract that metastasizes to the lungs and/or liver made by the method of claim 1 .

3. A method for determining whether a test agent is a candidate for inhibition of metastasis comprising providing a non-human animal of claim 2 , allowing metastasis of the orthotopic tumor to the lungs and/or liver, and after a period of time measuring metastasis of the tumor to the lungs and/or liver, wherein a reduction of metastasis relative to a control indicates that the test agent is a candidate for use as an inhibitor of metastasis of the tumor to the lungs and/or liver.

Assignments (2)
CONFIRMATORY LICENSE Recorded Sep 28, 2017
From: CORNELL UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 044037/0154 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 31, 2014
From: CHEN, HUANHUAN; LIPKIN, STEVEN M.; SHEN, XILING
To: CORNELL UNIVERSITY
Reel/Frame 034606/0850 →
Continuity (2)
Provisional Application 61668289 · Jul 5, 2012
Related Publication 20150164053A1 · Jun 18, 2015